国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global General

Special

Newsmaker

Asia Pacific

America

Middle East

Europe

Africa

Australia starts 1st H1N1 flu vaccine trials

(Agencies)
Updated: 2009-07-22 15:23

ADELAIDE, Australia: The world's first human trials of an A(H1N1) flu vaccine have begun in Australia, drug company officials said Wednesday, with the aim of controlling the virus that has so far killed more than 700 worldwide.

Two biotechnology companies have started injecting adult volunteers in the southern city of Adelaide with their vaccines. Adelaide-based Vaxine began trials Monday with 300 subjects, and Melbourne's CSL has 240 people in its seven-month trial, which started Wednesday. The companies say their trials are the first tests of an A(H1N1) flu vaccine on humans.

Full Coverage:  Flu Pandemic Outbreak Related readings:  Iran's influenza A(H1N1) patients amount to 16  36 new A(H1N1) cases confirmed in Europe  H1N1 flu continues to spread worldwide  WHO: H1N1 pandemic spreads at unprecedented speed  WHO:World manufacturing capacity for A/H1N1 flu vaccines is limited

At least 41 people have died in flu-related illness in Australia, which is well into its winter flu season.

"We're in the southern hemisphere, and that is where the problem is right now," Vaxine research director Nikolai Petrovsky told The Associated Press. "The demand was here yesterday. We're right in the middle of a surge of A(H1N1) flu cases where perhaps the United States won't have to worry about it as much until their flu season hits in six months."

Australia had confirmed 14,703 cases of A(H1N1) flu as of Wednesday. The worldwide death toll is more than 700, according to the World Health Organization, which recently stopped counting the number of cases worldwide. An explosion of cases is predicted in September and October, when students and workers in the northern hemisphere return from summer vacation.

CSL expects that initial results will allow distribution of its government-funded vaccine in October. The federal government has already ordered 21 million doses of CSL's vaccine for use in Australia, should it be proven to work.

"We have a specific vaccine that we believe will be able to protect millions of people against this new H1N1 flu," Andrew Cuthbertson, CSL's director of research and development, told reporters. He called A(H1N1) flu "a novel strain of influenza" and said the trial would determine the dose and schedule of the vaccination.

Vaxine's Petrovsky said it would be six to eight weeks before results would verify whether a vaccine was effective.

"There is no guarantee any of these vaccines will work," he said. "it's a very different virus that we're dealing with. But we are hopeful."

Medical experts warned against rushing the vaccines through trials.

"I think it's important for the public to know that they're going to get a safe and effective vaccine," Andrew Pesce, president of the Australian Medical Association, told Sky News television. "No one will give anybody brownie points for putting out a vaccine that didn't work or caused harm."